News and Insights of 3D Printing and Manufacturing
Over the last decade, 3D bioprinting has come on leaps and bounds, with significant advances being made in the development of viable, patient-specific soft tissues.
Canadian 3D bioprinting technology company Aspect Biosystems has announced its involvement in a $2.2 million project seeking to find new treatments for cancer. Starting this year, the company will be working with collaborators at two of the world’s largest pharmaceutical companies Merck and GSK, as well as McGill University’s Goodman Cancer Research Centre in Quebec.
Canadian 3D bioprinting company Aspect Biosystems has launched a new grant program whereby the selected applicants will be supplied with the company’s proprietary RX1 bioprinters.